Long‐term effects of ustekinumab in children with inflammatory bowel disease: A systematic review
Authors:
- Breno Oliveira MarquesBMBreno Oliveira Marques
- Ana Beatriz Ferreira GusmãoAGAna Beatriz Ferreira Gusmão
- Ana Luiza Ferreira GusmãoAGAna Luiza Ferreira Gusmão
- Bianca Ferraz de Almeida SilvaBSBianca Ferraz de Almeida Silva
- Gabrielle Silva SousaGSGabrielle Silva Sousa
- Jessica Sabrina Gonçalves FernandesJFJessica Sabrina Gonçalves Fernandes
- Nikolas Brayan da Silva BragasNBNikolas Brayan da Silva Bragas
- Natalia Oliveira e SilvaNSNatalia Oliveira e Silva
- 23 July 2025
- journal article
- review article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (4) , 1045-1059
Abstract
Ustekinumab, a monoclonal antibody used in adults, is increasingly employed in children and adolescents with refractory inflammatory bowel disease (IBD). This review aimed to analyze its long‐term efficacy and safety in the pediatric population. To this end, a systematic review was registered under PROSPERO (CRD42024555896). Articles indexed in PubMed/Medline, Cochrane Library, and Web of Science up to May 30, 2024, were screened. Quality was assessed using the Newcastle–Ottawa Scale. From 563 articles, 11 observational studies were included, analyzing 444 pediatric IBD patients. Remission rates varied: 47% at Week 16, 57%–59% at Week 26, and 40%–64% at Week 52. In addition, clinical improvements included better Z‐scores, body mass index, reduced inflammation, and healing of mucosal and perianal disease. Five studies standardized doses by weight: 260 mg (85 kg), with maintenance doses typically 90 mg every 8–12 weeks. Some patients received concomitant therapies (e.g., methotrexate, corticosteroids, and 5‐aminosalicylic acid). While adverse effects were reported, including worsening psoriasis, cutaneous and neurological reactions, infections, elevated transaminases, and lymphopenia. Severe adverse events were rare, though anaphylaxis and one death from acute diarrhea were reported. Overall, ustekinumab shows promising clinical and laboratory outcomes in pediatric IBD. However, long‐term studies are essential to solidify evidence regarding remission rates and adverse effects.Keywords
This publication has 30 references indexed in Scilit:
- Effectiveness and Safety of Ustekinumab in Pediatric Ulcerative Colitis: A Multi-center Retrospective Study from the Pediatric IBD Porto Group of ESPGHANPediatric Drugs, 2024
- STEP-CD study: ustekinumab use in paediatric Crohn’s disease—a multicentre retrospective study from paediatric IBD Porto group of ESPGHANEuropean Journal of Pediatrics, 2024
- Medical management of pediatric inflammatory bowel diseaseSeminars in Pediatric Surgery, 2024
- Real‐world effectiveness of ustekinumab and vedolizumab in TNF‐exposed pediatric patients with ulcerative colitisJournal of Pediatric Gastroenterology and Nutrition, 2024
- Epidemiology of Pediatric Inflammatory Bowel DiseaseGastroenterology Clinics of North America, 2023
- Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic ReviewPediatric Drugs, 2023
- Safety Summary of Pediatric Inflammatory Bowel Disease TherapiesGastroenterology Clinics of North America, 2023
- Inflammatory Bowel Disease in Children and AdolescentsAdvances in Pediatrics, 2021
- The Treatment of Pediatric Inflammatory Bowel Disease with Biologic TherapiesCurrent Gastroenterology Reports, 2020
- Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's DiseaseGastroenterology, 2018